We are live on
!
Find out more
ZCM
Zebra Capital Management Portfolio holdings
AUM
$20M
1-Year Est. Return
2.24%
This Fund
S&P 500
This Quarter
Est. Return
+18.5%
1 Year Est. Return
+2.24%
3 Year Est. Return
+142.1%
5 Year Est. Return
+107.07%
10 Year Est. Return
+252.16%
AUM
$90.8M
AUM Growth
+$12M
(+15%)
Cap. Flow
+$4.91M
Cap. Flow
% of AUM
5.41%
Top 10 Holdings %
Top 10 Hldgs %
18.38%
Holding
278
New
115
Increased
17
Reduced
37
Closed
109
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Emergent Biosolutions
EBS
|
+$2.15M |
| 2 |
Kelly Services Class A
KELYA
|
+$1.94M |
| 3 |
ESGR
Enstar Group
ESGR
|
+$1.61M |
| 4 |
LCI Industries
LCII
|
+$1.56M |
| 5 |
Upbound Group
UPBD
|
+$1.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WD-40
WDFC
|
+$1.47M |
| 2 |
Corcept Therapeutics
CORT
|
+$1.23M |
| 3 |
Veracyte
VCYT
|
+$1.22M |
| 4 |
Castle Biosciences
CSTL
|
+$1.03M |
| 5 |
CDMO
Avid Bioservices, Inc. Common Stock
CDMO
|
+$965K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.12% |
| 2 | Industrials | 15.8% |
| 3 | Financials | 14.75% |
| 4 | Consumer Discretionary | 13.38% |
| 5 | Technology | 12.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Kelly Services Class A
KELYA
$522M
| $2.03M | 2.24% |
+91,125
| New | +$1.94M |
|
|
2
Emergent Biosolutions
EBS
$387M
| $1.95M | 2.14% |
+20,957
| New | +$2.15M |
|
3
Rush Enterprises Class A
RUSHA
$5.93B
| $1.91M | 2.11% |
57,575
+27,446
| +91% | +$819K |
|
4
Insight Enterprises
NSIT
$3.49B
| $1.88M | 2.07% |
19,740
+4,789
| +32% | +$410K |
|
|
ESGR
5
DELISTED
Enstar Group
ESGR
| $1.75M | 1.93% |
+7,106
| New | +$1.61M |
|
|
CCRN
6
DELISTED
Cross Country Healthcare
CCRN
| $1.49M | 1.64% |
119,119
+32,100
| +37% | +$340K |
|
|
7
LCI Industries
LCII
$2.54B
| $1.47M | 1.62% |
+11,127
| New | +$1.56M |
|
|
8
Upbound Group
UPBD
$1.23B
| $1.46M | 1.61% |
+25,381
| New | +$1.33M |
|
9
Otter Tail
OTTR
$3.87B
| $1.39M | 1.53% |
+30,036
| New | +$1.28M |
|
10
Patrick Industries
PATK
$2.83B
| $1.36M | 1.5% |
+23,967
| New | +$1.26M |
|
11
Phibro Animal Health
PAHC
$1.38B
| $1.35M | 1.49% |
+55,442
| New | +$1.25M |
|
12
Donegal Group Class A
DGICA
$683M
| $1.31M | 1.45% |
88,303
+23,743
| +37% | +$340K |
|
|
BPMC
13
DELISTED
Blueprint Medicines
BPMC
| $1.24M | 1.36% |
+12,698
| New | +$1.27M |
|
14
Coca-Cola Consolidated
COKE
$11.9B
| $1.24M | 1.36% |
+42,760
| New | +$1.18M |
|
15
PC Connection
CNXN
$2.02B
| $1.22M | 1.34% |
+26,300
| New | +$1.3M |
|
|
NWLI
16
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $1.17M | 1.29% |
+4,712
| New | +$1.01M |
|
17
Forestar Group
FOR
$1.42B
| $1.16M | 1.27% |
+49,628
| New | +$1.11M |
|
18
Stepan Co
SCL
$1.31B
| $1.16M | 1.27% |
+9,088
| New | +$1.13M |
|
19
MYR Group
MYRG
$6.34B
| $1.12M | 1.23% |
15,621
+7,050
| +82% | +$446K |
|
20
Helen of Troy
HELE
$625M
| $1.08M | 1.19% |
+5,148
| New | +$1.16M |
|
|
PCH
21
DELISTED
PotlatchDeltic
PCH
| $1.05M | 1.16% |
19,893
+13,335
| +203% | +$688K |
|
22
Mueller Industries
MLI
$14B
| $1.05M | 1.15% |
101,208
+47,020
| +87% | +$462K |
|
|
SYKE
23
DELISTED
SYKES Enterprises Inc
SYKE
| $1.03M | 1.13% |
23,324
-7,444
| -24% | -$315K |
|
24
Myriad Genetics
MYGN
$538M
| $1.01M | 1.11% |
+33,060
| New | +$938K |
|
25
Weis Markets
WMK
$1.85B
| $1M | 1.1% |
17,710
+4,480
| +34% | +$240K |
|
Similar funds
CM
NPAM
6C
SCU
FFG
KE
GFT
CCM
Zebra Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Zebra Capital Management held 278 positions worth $90.8M, up 15% from $78.8M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Zebra Capital Management deployed $4.91M of net new capital in Q1 2021, opening 115 new positions and adding to 17 existing holdings. Its largest new stake was Emergent Biosolutions: 20,957 shares worth $1.95M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Veracyte, an estimated $1.22M trimmed.
- Zebra Capital Management's largest Q1 2021 buy was Emergent Biosolutions: 20,957 shares worth $1.95M.
- Zebra Capital Management added most to Rush Enterprises Class A in Q1 2021, an estimated $819K increase.
- Zebra Capital Management's biggest Q1 2021 reduction was Veracyte, cutting an estimated $1.22M.
- Zebra Capital Management fully exited WD-40 in Q1 2021, selling an estimated $1.47M.
- Zebra Capital Management's ten largest holdings make up 18% of its $90.8M portfolio in Q1 2021.
- Zebra Capital Management opened 115 new positions and closed 109 in Q1 2021.
- Zebra Capital Management's portfolio value rose 15% quarter-over-quarter to $90.8M.
Based on Zebra Capital Management's 13F filing for Q1 2021, filed 17 May 2021.